Project Grant R01FD008181
Award Date
9/15/24
Completion Date
7/31/28
Dollars Obligated
$191K
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award of $672,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research conducted by the Albert Einstein College of Medicine in Bronx, NY. The research project, titled "A Novel Synthetic Lethal Vulnerability Uncovered by Inhibiting One-Carbon Metabolism in Anaplastic Thyroid Cancer," aims to investigate a new therapeutic approach for treating this aggressive form of thyroid cancer. The...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,496,492.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on elucidating tumor-specific cell surface proteomes in ultra-rare cancers like rhabdoid tumors and desmoplastic small round cell tumors. The goal is to gain a better understanding of these challenging, therapy-resistant cancers and identify potential new therapeutic targets. The...
This Project Grant award, valued at $559,587.00, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Institute For Cancer Research (ICR), a non-profit research organization located in Cheltenham, Pennsylvania. The funding supports research aimed at investigating how thyroid hormone (TH) can induce differentiation and inhibit the growth of medulloblastoma, the most common malignant brain tumor in children. The key objectives are to: 1) Examine how TH...
The federal Project Grant award R21CA296696, totaling $219,351.00, was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The grant supports research to evaluate the toxicity, pharmacokinetic, and pharmacodynamic properties of the thyroid hormone T3, as well as investigate its therapeutic efficacy in combination with cytotoxic drugs or irradiation for the treatment of medulloblastoma, the most common malignant brain tumor in children. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $662,516 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on improving drug delivery for chemoradiotherapy in locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The project aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery, and test...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The research will evaluate how intrinsic tumor features contribute to the development of resistance, and test a novel combination approach of DNA repair inhibition and targeted therapy to prevent...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,489,181 in funding to Duke University, with a sub-award to Sloan-Kettering Institute for Cancer Research, to conduct research on malignant phyllodes tumors (MPT), a rare and aggressive form of breast cancer. The key objectives of the project are to: 1) define the genomic alterations in borderline phyllodes tumors and MPTs, and evaluate associations with clinical...
The National Cancer Institute (CFDA 93.395 Cancer Treatment Research) awarded a $267,298 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research aimed at targeting the CDK4/6 pathway in MIT/TFE-translocation renal cell carcinoma (TRCC), an aggressive and underserved form of kidney cancer. The research project will use genetic and pharmacologic approaches to test the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR pathway...